Anti-dsDNA antibodies in sarcoidosis
Identifieur interne : 002467 ( Istex/Corpus ); précédent : 002466; suivant : 002468Anti-dsDNA antibodies in sarcoidosis
Auteurs : Ido Weinberg ; Lena Vasiliev ; Israel GotsmanSource :
- Seminars in Arthritis and Rheumatism [ 0049-0172 ] ; 2000.
English descriptors
- KwdEn :
- Teeft :
- Antibody, Antidsdna antibodies, Antinuclear, Antinuclear antibodies, Average level, Biopsy, Chronic multisystem disorder, Clinical severity, Clinical symptoms, Definite diagnosis, Diffuse wheezes, Erythematosus, Gotsman, Granuloma, Hadassah, Hadassah university hospital, Heavy smoker, Hospitalization days, Immunoglobulin, Israel gotsman, Laboratory studies, Liver function tests, Lung disease, Lupus, Noncaseating, Noncaseating granuloma, Noncaseating granulomas, Normal limits, Normal subjects, Parotid glands, Physical examination, Rheum, Rheumatoid, Rheumatoid factor, Sarcoid, Sarcoid patients, Sarcoidosis, School hebrew university, Serological markers, Significant difference, Specific marker, Steroid, Steroid treatment, Systemic lupus erythematosus, Tissue biopsy, University hospital, Various antibodies.
Abstract
Background:Sarcoidosis is a chronic multisystem disorder characterized by an exaggerated cellular immune response to antigens with the production of various antibodies including rheumatoid factor and antinuclear antibodies (ANA). The prevalence and significance of antibodies to double-stranded DNA (anti-dsDNA) in sarcoid patients is unknown. The occurrence of anti-dsDNA antibodies is known to be a specific marker of systemic lupus erythematosus (SLE). Sarcoidosis can occur with SLE. It is unclear if anti-dsDNA antibodies in patients with sarcoidosis signify the eventual development of SLE.Objectives:To determine the prevalence of anti-dsDNA antibodies inpatients with sarcoidosis in a university hospital and their significance in predicting the diagnosis of associated SLE.Methods:In a retrospective study, 34 patient files with diagnosed sarcoidosis in a university hospital during a period of 15 years were reviewed for serological markers, including ANA, anti-dsDNA, and immunoglobulin and C3 levels. The occurrence of SLE in these patients also was evaluated.Results:ANA were positive in 10 of 34 of the patients screened. Two patientswith sarcoidosis had antibodies to dsDNA. C3 levels in these 34 patients were an average of 87.7 ± 25.3 mg/100 mL, which is within the normal range. IgG immunoglobulin levels were an average of 2,206 ± 999 mg/100 mL, which was above normal limits. The 2 patients who were positive for anti-dsDNA had normal C3 levels and SLE did not develop during a follow-up period of 10 to 15 years.Conclusions:Anti-dsDNA antibodies may occur in patients with sarcoidosis, but their presence does not predict the subsequent development of SLE.
Url:
DOI: 10.1016/S0049-0172(00)80019-0
Links to Exploration step
ISTEX:4F6907D663BA57E212B81D11B28CFAB844796A51Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-dsDNA antibodies in sarcoidosis</title><author><name sortKey="Weinberg, Ido" sort="Weinberg, Ido" uniqKey="Weinberg I" first="Ido" last="Weinberg">Ido Weinberg</name><affiliation><mods:affiliation>Division of Medicine, Hadassah University Hospital, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Hadassah Medical School, Hebrew University, Jerusalem, Israel</mods:affiliation></affiliation></author><author><name sortKey="Vasiliev, Lena" sort="Vasiliev, Lena" uniqKey="Vasiliev L" first="Lena" last="Vasiliev">Lena Vasiliev</name><affiliation><mods:affiliation>Division of Medicine, Hadassah University Hospital, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Medicine, Hadassah University Hospital, Jerusalem, Israel</mods:affiliation></affiliation></author><author><name sortKey="Gotsman, Israel" sort="Gotsman, Israel" uniqKey="Gotsman I" first="Israel" last="Gotsman">Israel Gotsman</name><affiliation><mods:affiliation>Division of Medicine, Hadassah University Hospital, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Division ofMedicine, Hadassah University Hospital, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Address reprint requests to Israel Gotsman, MD, Division ofMedicine, Hadassah University Hospital, PO Box 12000, Jerusalem, Israel 91120.</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: Igotsman@hadassah.org.il</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4F6907D663BA57E212B81D11B28CFAB844796A51</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1016/S0049-0172(00)80019-0</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-WW0BFJF9-J/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002467</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002467</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Anti-dsDNA antibodies in sarcoidosis</title><author><name sortKey="Weinberg, Ido" sort="Weinberg, Ido" uniqKey="Weinberg I" first="Ido" last="Weinberg">Ido Weinberg</name><affiliation><mods:affiliation>Division of Medicine, Hadassah University Hospital, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Hadassah Medical School, Hebrew University, Jerusalem, Israel</mods:affiliation></affiliation></author><author><name sortKey="Vasiliev, Lena" sort="Vasiliev, Lena" uniqKey="Vasiliev L" first="Lena" last="Vasiliev">Lena Vasiliev</name><affiliation><mods:affiliation>Division of Medicine, Hadassah University Hospital, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Medicine, Hadassah University Hospital, Jerusalem, Israel</mods:affiliation></affiliation></author><author><name sortKey="Gotsman, Israel" sort="Gotsman, Israel" uniqKey="Gotsman I" first="Israel" last="Gotsman">Israel Gotsman</name><affiliation><mods:affiliation>Division of Medicine, Hadassah University Hospital, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Division ofMedicine, Hadassah University Hospital, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Address reprint requests to Israel Gotsman, MD, Division ofMedicine, Hadassah University Hospital, PO Box 12000, Jerusalem, Israel 91120.</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: Igotsman@hadassah.org.il</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Seminars in Arthritis and Rheumatism</title><title level="j" type="abbrev">YSARH</title><idno type="ISSN">0049-0172</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">29</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="328">328</biblScope><biblScope unit="page" to="331">331</biblScope></imprint><idno type="ISSN">0049-0172</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0049-0172</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-double-stranded DNA antibodies</term><term>antinuclear antibodies</term><term>hyperglobulinemia</term><term>sarcoidosis</term><term>systemic lupus erythematosus</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Antibody</term><term>Antidsdna antibodies</term><term>Antinuclear</term><term>Antinuclear antibodies</term><term>Average level</term><term>Biopsy</term><term>Chronic multisystem disorder</term><term>Clinical severity</term><term>Clinical symptoms</term><term>Definite diagnosis</term><term>Diffuse wheezes</term><term>Erythematosus</term><term>Gotsman</term><term>Granuloma</term><term>Hadassah</term><term>Hadassah university hospital</term><term>Heavy smoker</term><term>Hospitalization days</term><term>Immunoglobulin</term><term>Israel gotsman</term><term>Laboratory studies</term><term>Liver function tests</term><term>Lung disease</term><term>Lupus</term><term>Noncaseating</term><term>Noncaseating granuloma</term><term>Noncaseating granulomas</term><term>Normal limits</term><term>Normal subjects</term><term>Parotid glands</term><term>Physical examination</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid factor</term><term>Sarcoid</term><term>Sarcoid patients</term><term>Sarcoidosis</term><term>School hebrew university</term><term>Serological markers</term><term>Significant difference</term><term>Specific marker</term><term>Steroid</term><term>Steroid treatment</term><term>Systemic lupus erythematosus</term><term>Tissue biopsy</term><term>University hospital</term><term>Various antibodies</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background:Sarcoidosis is a chronic multisystem disorder characterized by an exaggerated cellular immune response to antigens with the production of various antibodies including rheumatoid factor and antinuclear antibodies (ANA). The prevalence and significance of antibodies to double-stranded DNA (anti-dsDNA) in sarcoid patients is unknown. The occurrence of anti-dsDNA antibodies is known to be a specific marker of systemic lupus erythematosus (SLE). Sarcoidosis can occur with SLE. It is unclear if anti-dsDNA antibodies in patients with sarcoidosis signify the eventual development of SLE.Objectives:To determine the prevalence of anti-dsDNA antibodies inpatients with sarcoidosis in a university hospital and their significance in predicting the diagnosis of associated SLE.Methods:In a retrospective study, 34 patient files with diagnosed sarcoidosis in a university hospital during a period of 15 years were reviewed for serological markers, including ANA, anti-dsDNA, and immunoglobulin and C3 levels. The occurrence of SLE in these patients also was evaluated.Results:ANA were positive in 10 of 34 of the patients screened. Two patientswith sarcoidosis had antibodies to dsDNA. C3 levels in these 34 patients were an average of 87.7 ± 25.3 mg/100 mL, which is within the normal range. IgG immunoglobulin levels were an average of 2,206 ± 999 mg/100 mL, which was above normal limits. The 2 patients who were positive for anti-dsDNA had normal C3 levels and SLE did not develop during a follow-up period of 10 to 15 years.Conclusions:Anti-dsDNA antibodies may occur in patients with sarcoidosis, but their presence does not predict the subsequent development of SLE.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>sarcoidosis</json:string><json:string>lupus</json:string><json:string>erythematosus</json:string><json:string>hadassah</json:string><json:string>systemic lupus erythematosus</json:string><json:string>noncaseating</json:string><json:string>granuloma</json:string><json:string>immunoglobulin</json:string><json:string>definite diagnosis</json:string><json:string>sarcoid patients</json:string><json:string>sarcoid</json:string><json:string>rheumatoid</json:string><json:string>noncaseating granulomas</json:string><json:string>gotsman</json:string><json:string>university hospital</json:string><json:string>antinuclear</json:string><json:string>hadassah university hospital</json:string><json:string>serological markers</json:string><json:string>specific marker</json:string><json:string>antinuclear antibodies</json:string><json:string>rheumatoid factor</json:string><json:string>hospitalization days</json:string><json:string>various antibodies</json:string><json:string>chronic multisystem disorder</json:string><json:string>rheum</json:string><json:string>biopsy</json:string><json:string>israel gotsman</json:string><json:string>tissue biopsy</json:string><json:string>clinical symptoms</json:string><json:string>normal limits</json:string><json:string>significant difference</json:string><json:string>average level</json:string><json:string>heavy smoker</json:string><json:string>physical examination</json:string><json:string>diffuse wheezes</json:string><json:string>parotid glands</json:string><json:string>laboratory studies</json:string><json:string>clinical severity</json:string><json:string>noncaseating granuloma</json:string><json:string>school hebrew university</json:string><json:string>liver function tests</json:string><json:string>normal subjects</json:string><json:string>lung disease</json:string><json:string>steroid treatment</json:string><json:string>antidsdna antibodies</json:string><json:string>steroid</json:string><json:string>antibody</json:string></teeft></keywords><author><json:item><name>Ido Weinberg MSc</name><affiliations><json:string>Division of Medicine, Hadassah University Hospital, Israel</json:string><json:string>Hadassah Medical School, Hebrew University; Jerusalem, Israel</json:string><json:string>Hadassah Medical School, Hebrew University, Jerusalem, Israel</json:string></affiliations></json:item><json:item><name>Lena Vasiliev MD</name><affiliations><json:string>Division of Medicine, Hadassah University Hospital, Israel</json:string><json:string>Hadassah Medical School, Hebrew University; Jerusalem, Israel</json:string><json:string>Division of Medicine, Hadassah University Hospital, Jerusalem, Israel</json:string></affiliations></json:item><json:item><name>Israel Gotsman MD</name><affiliations><json:string>Division of Medicine, Hadassah University Hospital, Israel</json:string><json:string>Hadassah Medical School, Hebrew University; Jerusalem, Israel</json:string><json:string>Division ofMedicine, Hadassah University Hospital, Israel</json:string><json:string>Hadassah Medical School, Hebrew University; Jerusalem, Israel</json:string><json:string>Address reprint requests to Israel Gotsman, MD, Division ofMedicine, Hadassah University Hospital, PO Box 12000, Jerusalem, Israel 91120.</json:string><json:string>E-mail: Igotsman@hadassah.org.il</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Anti-double-stranded DNA antibodies</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>sarcoidosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>antinuclear antibodies</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>hyperglobulinemia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>systemic lupus erythematosus</value></json:item></subject><articleId><json:string>00800190</json:string></articleId><arkIstex>ark:/67375/6H6-WW0BFJF9-J</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Background:Sarcoidosis is a chronic multisystem disorder characterized by an exaggerated cellular immune response to antigens with the production of various antibodies including rheumatoid factor and antinuclear antibodies (ANA). The prevalence and significance of antibodies to double-stranded DNA (anti-dsDNA) in sarcoid patients is unknown. The occurrence of anti-dsDNA antibodies is known to be a specific marker of systemic lupus erythematosus (SLE). Sarcoidosis can occur with SLE. It is unclear if anti-dsDNA antibodies in patients with sarcoidosis signify the eventual development of SLE.Objectives:To determine the prevalence of anti-dsDNA antibodies inpatients with sarcoidosis in a university hospital and their significance in predicting the diagnosis of associated SLE.Methods:In a retrospective study, 34 patient files with diagnosed sarcoidosis in a university hospital during a period of 15 years were reviewed for serological markers, including ANA, anti-dsDNA, and immunoglobulin and C3 levels. The occurrence of SLE in these patients also was evaluated.Results:ANA were positive in 10 of 34 of the patients screened. Two patientswith sarcoidosis had antibodies to dsDNA. C3 levels in these 34 patients were an average of 87.7 ± 25.3 mg/100 mL, which is within the normal range. IgG immunoglobulin levels were an average of 2,206 ± 999 mg/100 mL, which was above normal limits. The 2 patients who were positive for anti-dsDNA had normal C3 levels and SLE did not develop during a follow-up period of 10 to 15 years.Conclusions:Anti-dsDNA antibodies may occur in patients with sarcoidosis, but their presence does not predict the subsequent development of SLE.</abstract><qualityIndicators><score>7.228</score><pdfWordCount>2288</pdfWordCount><pdfCharCount>14780</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>4</pdfPageCount><pdfPageSize>540 x 756 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>245</abstractWordCount><abstractCharCount>1677</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Anti-dsDNA antibodies in sarcoidosis</title><pmid><json:string>10805357</json:string></pmid><pii><json:string>S0049-0172(00)80019-0</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Seminars in Arthritis and Rheumatism</title><language><json:string>unknown</json:string></language><publicationDate>2000</publicationDate><issn><json:string>0049-0172</json:string></issn><pii><json:string>S0049-0172(00)X0164-3</json:string></pii><volume>29</volume><issue>5</issue><pages><first>328</first><last>331</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2000</json:string><json:string>1982</json:string></date><geogName></geogName><orgName><json:string>Hadassah Medical School Hebrew University</json:string><json:string>Division of Medicine</json:string><json:string>Hebrew University</json:string><json:string>Hadassah University Hospital Jerusalem, Israel</json:string><json:string>Research Fellow, Hadassah Medical School Hebrew University, Jerusalem, Israel</json:string><json:string>Hadassah University Hospital, PO Box</json:string><json:string>Hadassah University Hospital, Jerusalem, Israel</json:string><json:string>Hadassah University</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Lena Vasiliev</json:string><json:string>Brief</json:string><json:string>Israel Gotsman</json:string></persName><placeName><json:string>Jerusalem</json:string><json:string>Israel</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Veien et al</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-WW0BFJF9-J</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - rheumatology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - arthritis & rheumatology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Anesthesiology and Pain Medicine</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Rheumatology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1016/S0049-0172(00)80019-0</json:string></doi><id>4F6907D663BA57E212B81D11B28CFAB844796A51</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-WW0BFJF9-J/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-WW0BFJF9-J/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-WW0BFJF9-J/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Anti-dsDNA antibodies in sarcoidosis</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>©2000 W.B. Saunders Company</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</p></availability><date>2000</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Anti-dsDNA antibodies in sarcoidosis</title><author xml:id="author-0000"><persName><forename type="first">Ido</forename><surname>Weinberg</surname></persName><roleName type="degree">MSc</roleName><note type="biography">Research Fellow</note><affiliation>Research Fellow</affiliation><affiliation>Division of Medicine, Hadassah University Hospital, Israel</affiliation><affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</affiliation><affiliation>Hadassah Medical School, Hebrew University, Jerusalem, Israel</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Lena</forename><surname>Vasiliev</surname></persName><roleName type="degree">MD</roleName><note type="biography">Senior Medical Resident</note><affiliation>Senior Medical Resident</affiliation><affiliation>Division of Medicine, Hadassah University Hospital, Israel</affiliation><affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</affiliation><affiliation>Division of Medicine, Hadassah University Hospital, Jerusalem, Israel</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Israel</forename><surname>Gotsman</surname></persName><roleName type="degree">MD</roleName><email>Igotsman@hadassah.org.il</email><note type="biography">Chief Medical Resident and clinical instructor</note><affiliation>Chief Medical Resident and clinical instructor</affiliation><affiliation>Division of Medicine, Hadassah University Hospital, Israel</affiliation><affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</affiliation><affiliation>Division ofMedicine, Hadassah University Hospital, Israel</affiliation><affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</affiliation><affiliation>Address reprint requests to Israel Gotsman, MD, Division ofMedicine, Hadassah University Hospital, PO Box 12000, Jerusalem, Israel 91120.</affiliation></author><idno type="istex">4F6907D663BA57E212B81D11B28CFAB844796A51</idno><idno type="ark">ark:/67375/6H6-WW0BFJF9-J</idno><idno type="DOI">10.1016/S0049-0172(00)80019-0</idno><idno type="PII">S0049-0172(00)80019-0</idno><idno type="article-id">00800190</idno></analytic><monogr><title level="j">Seminars in Arthritis and Rheumatism</title><title level="j" type="abbrev">YSARH</title><idno type="pISSN">0049-0172</idno><idno type="PII">S0049-0172(00)X0164-3</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000"></date><biblScope unit="volume">29</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="328">328</biblScope><biblScope unit="page" to="331">331</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Background:Sarcoidosis is a chronic multisystem disorder characterized by an exaggerated cellular immune response to antigens with the production of various antibodies including rheumatoid factor and antinuclear antibodies (ANA). The prevalence and significance of antibodies to double-stranded DNA (anti-dsDNA) in sarcoid patients is unknown. The occurrence of anti-dsDNA antibodies is known to be a specific marker of systemic lupus erythematosus (SLE). Sarcoidosis can occur with SLE. It is unclear if anti-dsDNA antibodies in patients with sarcoidosis signify the eventual development of SLE.Objectives:To determine the prevalence of anti-dsDNA antibodies inpatients with sarcoidosis in a university hospital and their significance in predicting the diagnosis of associated SLE.Methods:In a retrospective study, 34 patient files with diagnosed sarcoidosis in a university hospital during a period of 15 years were reviewed for serological markers, including ANA, anti-dsDNA, and immunoglobulin and C3 levels. The occurrence of SLE in these patients also was evaluated.Results:ANA were positive in 10 of 34 of the patients screened. Two patientswith sarcoidosis had antibodies to dsDNA. C3 levels in these 34 patients were an average of 87.7 ± 25.3 mg/100 mL, which is within the normal range. IgG immunoglobulin levels were an average of 2,206 ± 999 mg/100 mL, which was above normal limits. The 2 patients who were positive for anti-dsDNA had normal C3 levels and SLE did not develop during a follow-up period of 10 to 15 years.Conclusions:Anti-dsDNA antibodies may occur in patients with sarcoidosis, but their presence does not predict the subsequent development of SLE.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Index words</head><item><term>Anti-double-stranded DNA antibodies</term></item><item><term>sarcoidosis</term></item><item><term>antinuclear antibodies</term></item><item><term>hyperglobulinemia</term></item><item><term>systemic lupus erythematosus</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2000">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-WW0BFJF9-J/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier doc found" wicri:toSee="Elsevier, no converted or simple article"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 5.0.1//EN//XML" URI="art501.dtd" name="istex:docType"></istex:docType><istex:document><article version="5.0" xml:lang="en" docsubtype="fla"><item-info><jid>YSARH</jid><aid>00800190</aid><ce:pii>S0049-0172(00)80019-0</ce:pii><ce:doi>10.1016/S0049-0172(00)80019-0</ce:doi><ce:copyright type="unknown" year="2000">W.B. Saunders Company</ce:copyright></item-info><head><ce:title>Anti-dsDNA antibodies in sarcoidosis</ce:title><ce:author-group><ce:author><ce:degrees>MSc</ce:degrees><ce:given-name>Ido</ce:given-name><ce:surname>Weinberg</ce:surname><ce:roles>Research Fellow</ce:roles><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2"><ce:sup>b</ce:sup></ce:cross-ref><ce:cross-ref refid="aff3"><ce:sup>c</ce:sup></ce:cross-ref></ce:author><ce:author><ce:degrees>MD</ce:degrees><ce:given-name>Lena</ce:given-name><ce:surname>Vasiliev</ce:surname><ce:roles>Senior Medical Resident</ce:roles><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2"><ce:sup>b</ce:sup></ce:cross-ref><ce:cross-ref refid="aff4"><ce:sup>d</ce:sup></ce:cross-ref></ce:author><ce:author><ce:degrees>MD</ce:degrees><ce:given-name>Israel</ce:given-name><ce:surname>Gotsman</ce:surname><ce:roles>Chief Medical Resident and clinical instructor</ce:roles><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2"><ce:sup>b</ce:sup></ce:cross-ref><ce:cross-ref refid="aff5"><ce:sup>e</ce:sup></ce:cross-ref><ce:cross-ref refid="aff6"><ce:sup>f</ce:sup></ce:cross-ref><ce:cross-ref refid="cor1"><ce:sup>*</ce:sup></ce:cross-ref><ce:e-address type="email">Igotsman@hadassah.org.il</ce:e-address></ce:author><ce:affiliation id="aff1"><ce:label>a</ce:label><ce:textfn>Division of Medicine, Hadassah University Hospital, Israel</ce:textfn></ce:affiliation><ce:affiliation id="aff2"><ce:label>b</ce:label><ce:textfn>Hadassah Medical School, Hebrew University; Jerusalem, Israel</ce:textfn></ce:affiliation><ce:affiliation id="aff3"><ce:label>c</ce:label><ce:textfn>Hadassah Medical School, Hebrew University, Jerusalem, Israel</ce:textfn></ce:affiliation><ce:affiliation id="aff4"><ce:label>d</ce:label><ce:textfn>Division of Medicine, Hadassah University Hospital, Jerusalem, Israel</ce:textfn></ce:affiliation><ce:affiliation id="aff5"><ce:label>e</ce:label><ce:textfn>Division ofMedicine, Hadassah University Hospital, Israel</ce:textfn></ce:affiliation><ce:affiliation id="aff6"><ce:label>f</ce:label><ce:textfn>Hadassah Medical School, Hebrew University; Jerusalem, Israel</ce:textfn></ce:affiliation><ce:correspondence id="cor1"><ce:label>*</ce:label><ce:text>Address reprint requests to Israel Gotsman, MD, Division ofMedicine, Hadassah University Hospital, PO Box 12000, Jerusalem, Israel 91120.</ce:text></ce:correspondence></ce:author-group><ce:abstract id="ab1" class="author" xml:lang="en"><ce:abstract-sec><ce:section-title>Background:</ce:section-title><ce:simple-para>Sarcoidosis is a chronic multisystem disorder characterized by an exaggerated cellular immune response to antigens with the production of various antibodies including rheumatoid factor and antinuclear antibodies (ANA). The prevalence and significance of antibodies to double-stranded DNA (anti-dsDNA) in sarcoid patients is unknown. The occurrence of anti-dsDNA antibodies is known to be a specific marker of systemic lupus erythematosus (SLE). Sarcoidosis can occur with SLE. It is unclear if anti-dsDNA antibodies in patients with sarcoidosis signify the eventual development of SLE.</ce:simple-para></ce:abstract-sec><ce:abstract-sec><ce:section-title>Objectives:</ce:section-title><ce:simple-para>To determine the prevalence of anti-dsDNA antibodies inpatients with sarcoidosis in a university hospital and their significance in predicting the diagnosis of associated SLE.</ce:simple-para></ce:abstract-sec><ce:abstract-sec><ce:section-title>Methods:</ce:section-title><ce:simple-para>In a retrospective study, 34 patient files with diagnosed sarcoidosis in a university hospital during a period of 15 years were reviewed for serological markers, including ANA, anti-dsDNA, and immunoglobulin and C3 levels. The occurrence of SLE in these patients also was evaluated.</ce:simple-para></ce:abstract-sec><ce:abstract-sec><ce:section-title>Results:</ce:section-title><ce:simple-para>ANA were positive in 10 of 34 of the patients screened. Two patientswith sarcoidosis had antibodies to dsDNA. C3 levels in these 34 patients were an average of 87.7 ± 25.3 mg/100 mL, which is within the normal range. IgG immunoglobulin levels were an average of 2,206 ± 999 mg/100 mL, which was above normal limits. The 2 patients who were positive for anti-dsDNA had normal C3 levels and SLE did not develop during a follow-up period of 10 to 15 years.</ce:simple-para></ce:abstract-sec><ce:abstract-sec><ce:section-title>Conclusions:</ce:section-title><ce:simple-para>Anti-dsDNA antibodies may occur in patients with sarcoidosis, but their presence does not predict the subsequent development of SLE.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="idt" xml:lang="en"><ce:section-title>Index words</ce:section-title><ce:keyword><ce:text>Anti-double-stranded DNA antibodies</ce:text></ce:keyword><ce:keyword><ce:text>sarcoidosis</ce:text></ce:keyword><ce:keyword><ce:text>antinuclear antibodies</ce:text></ce:keyword><ce:keyword><ce:text>hyperglobulinemia</ce:text></ce:keyword><ce:keyword><ce:text>systemic lupus erythematosus</ce:text></ce:keyword></ce:keywords></head><tail><ce:bibliography><ce:section-title>References</ce:section-title><ce:bibliography-sec><ce:bib-reference id="bib1"><ce:label>1.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Mathur</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Kremer</ce:surname><ce:given-name>J.M.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Immunopathology, musculoskeletal features, and treatment of sarcoidosis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Curr Opin Rheumatol</sb:maintitle></sb:title><sb:volume-nr>5</sb:volume-nr></sb:series><sb:date>1993</sb:date></sb:issue><sb:pages><sb:first-page>90</sb:first-page><sb:last-page>94</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>2.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Giotaki</ce:surname><ce:given-name>H.A.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Biochemical and immunological parameters of sarcoid patients in west Greece</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Sarcoidosis</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>135</sb:first-page><sb:last-page>137</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>3.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Zonana-Nacaeh</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Salas</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:author><ce:surname>Sanchez</ce:surname><ce:given-name>M.L.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Measurement of clinical activity of systemic lupus erythematosus and laboratory abnormalities: A 12-month prospective study</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Rheumatol</sb:maintitle></sb:title><sb:volume-nr>22</sb:volume-nr></sb:series><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>45</sb:first-page><sb:last-page>49</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>4.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Chida</ce:surname><ce:given-name>K.</ce:given-name></sb:author><sb:author><ce:surname>Sato</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Yasuda</ce:surname><ce:given-name>K.</ce:given-name></sb:author><sb:author><ce:surname>Shici</ce:surname><ce:given-name>I.</ce:given-name></sb:author><sb:author><ce:surname>Iwata</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:author><ce:surname>Gemma</ce:surname><ce:given-name>H.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Clinical aspects of sarcoidosis with autoantibodies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nihon Kyobu Shikkan Gakkai Zasshi</sb:maintitle></sb:title><sb:volume-nr>27</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>194</sb:first-page><sb:last-page>199</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>5.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Olenchock</ce:surname><ce:given-name>S.A.</ce:given-name></sb:author><sb:author><ce:surname>Marx</ce:surname><ce:given-name>J.J.</ce:given-name><ce:suffix>Jr.</ce:suffix></sb:author><sb:author><ce:surname>Mull</ce:surname><ce:given-name>J.C.</ce:given-name></sb:author><sb:author><ce:surname>Mentnech</ce:surname><ce:given-name>M.S.</ce:given-name></sb:author><sb:author><ce:surname>Spurgeon</ce:surname><ce:given-name>D.E.</ce:given-name></sb:author><sb:author><ce:surname>Gladish</ce:surname><ce:given-name>M.E.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Immunology of clinically inactive sarcoidosis: Serum factors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann Allergy</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:date>1981</sb:date></sb:issue><sb:pages><sb:first-page>28</sb:first-page><sb:last-page>31</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>6.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Ginsberg</ce:surname><ce:given-name>B.</ce:given-name></sb:author><sb:author><ce:surname>Keiser</ce:surname><ce:given-name>H.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>A millipore filter assay for antibodies to native DNA in sera of patients with systemic lupus erythematosus</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Arthritis Rheum</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>1973</sb:date></sb:issue><sb:pages><sb:first-page>199</sb:first-page><sb:last-page>207</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>7.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Tan</ce:surname><ce:given-name>E.M.</ce:given-name></sb:author><sb:author><ce:surname>Cohen</ce:surname><ce:given-name>A.S.</ce:given-name></sb:author><sb:author><ce:surname>Fries</ce:surname><ce:given-name>J.F.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>The 1982 revised criteria for the classification of systemic lupus erythematosus</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Arthritis Rheum</sb:maintitle></sb:title><sb:volume-nr>25</sb:volume-nr></sb:series><sb:date>1982</sb:date></sb:issue><sb:pages><sb:first-page>1271</sb:first-page><sb:last-page>1277</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>8.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Snedecor</ce:surname><ce:given-name>W.G.</ce:given-name></sb:author><sb:author><ce:surname>Cochran</ce:surname><ce:given-name>G.W.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Statistical methods</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:edition>6th ed</sb:edition><sb:date>1967</sb:date><sb:publisher><sb:name>The Iowa State, University Press</sb:name><sb:location>Ames, Iowa</sb:location></sb:publisher></sb:edited-book><sb:pages><sb:first-page>128</sb:first-page><sb:last-page>132</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>9.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Veien</ce:surname><ce:given-name>N.K.</ce:given-name></sb:author><sb:author><ce:surname>Hardt</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:author><ce:surname>Bendixen</ce:surname><ce:given-name>G.</ce:given-name></sb:author><sb:author><ce:surname>Genner</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>Ringsted</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>Wanstrup</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Humoral and cellular immunity in sarcoidosis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Acta Med Scand</sb:maintitle></sb:title><sb:volume-nr>203</sb:volume-nr></sb:series><sb:date>1978</sb:date></sb:issue><sb:pages><sb:first-page>321</sb:first-page><sb:last-page>326</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>10.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Carson</ce:surname><ce:given-name>A.D.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>The specificity of anti-DNA antibodies in SLE</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Immunol</sb:maintitle></sb:title><sb:volume-nr>146</sb:volume-nr></sb:series><sb:date>1991</sb:date></sb:issue><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>2</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>11.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Reeves</ce:surname><ce:given-name>W.H.</ce:given-name></sb:author><sb:author><ce:surname>Satoh</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:author><ce:surname>Jinsong</ce:surname><ce:given-name>W.</ce:given-name></sb:author><sb:author><ce:surname>Chou</ce:surname><ce:given-name>C.</ce:given-name></sb:author><sb:author><ce:surname>Ajmanik</ce:surname><ce:given-name>A.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Antibodies to DNA, DNA binding proteins and histones</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Rheum Dis Clin North Am</sb:maintitle></sb:title><sb:volume-nr>20</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>28</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>12.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Tan</ce:surname><ce:given-name>E.A.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Autoantibodies to nuclear antigens: Their biology and medicine</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Adv Immunol</sb:maintitle></sb:title><sb:volume-nr>33</sb:volume-nr></sb:series><sb:date>1982</sb:date></sb:issue><sb:pages><sb:first-page>167</sb:first-page><sb:last-page>240</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>13.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Koffler</ce:surname><ce:given-name>D.</ce:given-name></sb:author><sb:author><ce:surname>Carr</ce:surname><ce:given-name>I.R.</ce:given-name></sb:author><sb:author><ce:surname>Angello</ce:surname><ce:given-name>V.</ce:given-name></sb:author><sb:author><ce:surname>Fiezi</ce:surname><ce:given-name>T.</ce:given-name></sb:author><sb:author><ce:surname>Kundel</ce:surname><ce:given-name>H.G.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Antibodies to polynueleotides: Distribution in human serums</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Science</sb:maintitle></sb:title><sb:volume-nr>166</sb:volume-nr></sb:series><sb:date>1969</sb:date></sb:issue><sb:pages><sb:first-page>1648</sb:first-page><sb:last-page>1649</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib14"><ce:label>14.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Schnabel</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Barth</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>Schubert</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:author><ce:surname>Gross</ce:surname><ce:given-name>W.L.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Pulmonary sarcoidosix coexisting with systemic lupus erythematosus</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Scand J Rheumatol</sb:maintitle></sb:title><sb:volume-nr>25</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>109</sb:first-page><sb:last-page>111</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib15"><ce:label>15.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Fivenson</ce:surname><ce:given-name>D.P.</ce:given-name></sb:author><sb:author><ce:surname>Crump</ce:surname><ce:given-name>G.</ce:given-name></sb:author><sb:author><ce:surname>Scheele</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:author><ce:surname>Breneman</ce:surname><ce:given-name>D.L.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Systemic lupus erythematosus developing in a patient with longstanding pulmonary sarcoidosis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Rheumatol</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>1116</sb:first-page><sb:last-page>1119</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib16"><ce:label>16.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Askari</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Thompson</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:author><ce:surname>Barnes</ce:surname><ce:given-name>C.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Sarcoidosis: Atypical pressentation associated with features of systemic of lupus erythematosus</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Rheumatol</sb:maintitle></sb:title><sb:volume-nr>15</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>1578</sb:first-page><sb:last-page>1579</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib17"><ce:label>17.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Soto-Aguilar</ce:surname><ce:given-name>M.C.</ce:given-name></sb:author><sb:author><ce:surname>Boulware</ce:surname><ce:given-name>D.W.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Sarcoidosis presenting as antinuclear antibody positive glometulonephritis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann Rheum Dis</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>337</sb:first-page><sb:last-page>339</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Anti-dsDNA antibodies in sarcoidosis</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Anti-dsDNA antibodies in sarcoidosis</title></titleInfo><name type="personal"><namePart type="given">Ido</namePart><namePart type="family">Weinberg</namePart><namePart type="termsOfAddress">MSc</namePart><affiliation>Division of Medicine, Hadassah University Hospital, Israel</affiliation><affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</affiliation><affiliation>Hadassah Medical School, Hebrew University, Jerusalem, Israel</affiliation><description>Research Fellow</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lena</namePart><namePart type="family">Vasiliev</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Division of Medicine, Hadassah University Hospital, Israel</affiliation><affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</affiliation><affiliation>Division of Medicine, Hadassah University Hospital, Jerusalem, Israel</affiliation><description>Senior Medical Resident</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Israel</namePart><namePart type="family">Gotsman</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Division of Medicine, Hadassah University Hospital, Israel</affiliation><affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</affiliation><affiliation>Division ofMedicine, Hadassah University Hospital, Israel</affiliation><affiliation>Hadassah Medical School, Hebrew University; Jerusalem, Israel</affiliation><affiliation>Address reprint requests to Israel Gotsman, MD, Division ofMedicine, Hadassah University Hospital, PO Box 12000, Jerusalem, Israel 91120.</affiliation><affiliation>E-mail: Igotsman@hadassah.org.il</affiliation><description>Chief Medical Resident and clinical instructor</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2000</dateIssued><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Background:Sarcoidosis is a chronic multisystem disorder characterized by an exaggerated cellular immune response to antigens with the production of various antibodies including rheumatoid factor and antinuclear antibodies (ANA). The prevalence and significance of antibodies to double-stranded DNA (anti-dsDNA) in sarcoid patients is unknown. The occurrence of anti-dsDNA antibodies is known to be a specific marker of systemic lupus erythematosus (SLE). Sarcoidosis can occur with SLE. It is unclear if anti-dsDNA antibodies in patients with sarcoidosis signify the eventual development of SLE.Objectives:To determine the prevalence of anti-dsDNA antibodies inpatients with sarcoidosis in a university hospital and their significance in predicting the diagnosis of associated SLE.Methods:In a retrospective study, 34 patient files with diagnosed sarcoidosis in a university hospital during a period of 15 years were reviewed for serological markers, including ANA, anti-dsDNA, and immunoglobulin and C3 levels. The occurrence of SLE in these patients also was evaluated.Results:ANA were positive in 10 of 34 of the patients screened. Two patientswith sarcoidosis had antibodies to dsDNA. C3 levels in these 34 patients were an average of 87.7 ± 25.3 mg/100 mL, which is within the normal range. IgG immunoglobulin levels were an average of 2,206 ± 999 mg/100 mL, which was above normal limits. The 2 patients who were positive for anti-dsDNA had normal C3 levels and SLE did not develop during a follow-up period of 10 to 15 years.Conclusions:Anti-dsDNA antibodies may occur in patients with sarcoidosis, but their presence does not predict the subsequent development of SLE.</abstract><subject lang="en"><genre>Index words</genre><topic>Anti-double-stranded DNA antibodies</topic><topic>sarcoidosis</topic><topic>antinuclear antibodies</topic><topic>hyperglobulinemia</topic><topic>systemic lupus erythematosus</topic></subject><relatedItem type="host"><titleInfo><title>Seminars in Arthritis and Rheumatism</title></titleInfo><titleInfo type="abbreviated"><title>YSARH</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2000</dateIssued></originInfo><identifier type="ISSN">0049-0172</identifier><identifier type="PII">S0049-0172(00)X0164-3</identifier><part><date>2000</date><detail type="volume"><number>29</number><caption>vol.</caption></detail><detail type="issue"><number>5</number><caption>no.</caption></detail><extent unit="issue-pages"><start>267</start><end>334</end></extent><extent unit="pages"><start>328</start><end>331</end></extent></part></relatedItem><identifier type="istex">4F6907D663BA57E212B81D11B28CFAB844796A51</identifier><identifier type="ark">ark:/67375/6H6-WW0BFJF9-J</identifier><identifier type="DOI">10.1016/S0049-0172(00)80019-0</identifier><identifier type="PII">S0049-0172(00)80019-0</identifier><identifier type="ArticleID">00800190</identifier><accessCondition type="use and reproduction" contentType="copyright">©2000 W.B. Saunders Company</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource><recordOrigin>W.B. Saunders Company, ©2000</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-WW0BFJF9-J/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002467 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002467 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:4F6907D663BA57E212B81D11B28CFAB844796A51
|texte= Anti-dsDNA antibodies in sarcoidosis
}}
| This area was generated with Dilib version V0.6.33. |  |